Key Highlights

  • PepGen (NASDAQ:PEPG) closed at USD 6.21 on Tuesday, November 10, 2026, up 159.83% from a calculated prior close of USD 2.39, among the largest gainers in a published screener snapshot of 4,625 names.
  • Volume reached 67.27 million shares at a relative Volume of 65.22, which implies a recent average near 1.03 million shares (calculated), and about USD 417.7 million of shares changed hands at the closing price (calculated).
  • The snapshot shows a Market Value of USD 165.53 million, trailing diluted EPS of USD -1.31, EPS growth of +56.00%, no P/E ratio and a Dividend Yield of 0.00%.
  • No release, filing or published coverage dated November 9 or November 10, 2026 was identified, so the move is described here as having no identified catalyst.

What Moved PepGen on November 10 (+159.83%)

PepGen is a Boston-based clinical-stage biotechnology company, founded in 2018, that develops oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. It has 56 employees. The shares ended Tuesday at USD 6.21, up 159.83%. Simple arithmetic on those two published numbers gives a prior close of about USD 2.39 on Monday, November 9, 2026, a gain of roughly USD 3.82 per share. A published quote on November 3, 2026 showed USD 2.40 with a day range of USD 2.36 to USD 2.45 and volume of only 27.06 thousand shares against an average of 1.16 million, so Tuesday's 67.27 million shares is about 58 times that average (calculated).

The Rationale: No Catalyst Identified in Published Coverage

Two searches found no company release, 8-K or published coverage dated November 9 or November 10, 2026 that explains the move, so no catalyst is identified in published coverage. As general context, a gain above 100% in a clinical-stage biotech usually follows one of a few events: clinical data, a regulatory update, a Partnership or licensing deal, an Acquisition approach, or a financing at a premium. Short covering and retail order flow can add to a spike. None of these is confirmed for PepGen (NASDAQ:PEPG), and the absence of a named trigger is itself a risk, because a move without a disclosed reason can retrace quickly if no news follows.

Valuation, Liquidity and Risks for PepGen

The row lists a market value of USD 165.53 million, which matches the November 3 quote of USD 166.22 million at USD 2.40, so it appears to rest on the earlier price. That implies about 69.3 million shares (calculated). At USD 6.21 the same count would be worth roughly USD 430 million (calculated), so size figures should be treated as unconfirmed. The 52-week range was USD 1.31 to USD 7.80 on November 3, which puts USD 6.21 at about 80% of the high and 4.74 times the low. With no profit, a P/E near -1.8 and a trailing loss of USD 1.31 a share, valuation rests on pipeline expectations. Clinical-stage companies often raise Equity after sharp rallies, which dilutes holders, and a gain this large does not imply it will continue.

Where Things Stand

The answer to why PepGen (NASDAQ:PEPG) soared 159.83% on November 10, 2026 is that no catalyst was identified in published coverage. The stock closed at USD 6.21 on 67.27 million shares, about 65 times its recent average volume, and sits near the USD 7.80 high of its 52-week range. A move on this volume with no disclosed reason can reverse, and any financing would dilute holders.